Literature DB >> 16687200

Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis.

Jirí Spacek1, Vladimír Buchta, Petr Jílek, Miroslav Förstl.   

Abstract

OBJECTIVE: This study was undertaken to characterize the patients with recurrent vulvovaginal candidiasis. STUDY
DESIGN: Basic data of personal history and history of recurrent vulvovaginal candidiasis, lower genital tract symptoms and signs in 50 patients were analyzed in this longitudinal follow-up study including the determination of midluteal serum progesterone and urinary pregnanediol levels during the luteal phase in 84 cycles (recurrent vulvovaginal candidiasis) and 60 cycles (healthy controls).
RESULTS: All patients suffered primary idiopathic form of recurrent vulvovaginal candidiasis. Frequently, there was a striking discrepancy between severe symptoms and clinical finding, which was often negligible or normal. There was no redness and no or minimum discharge in 52% of culture documented attacks. In contrast to the healthy controls, the patients had significantly lower levels of progesterone (p<0.01) as well as those of urinary pregnanediol (p<0.05).
CONCLUSION: Culture positive attacks in patients with recurrent vulvovaginal candidiasis represented rather a form of vulvovaginal discomfort than attacks of vulvovaginal candidiasis with typical inflammatory changes. Significantly lower progesterone levels in the RVVC patients as compared to the healthy controls suggest a link between an altered hormonal status and one of possible causes of RVVC in these women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687200     DOI: 10.1016/j.ejogrb.2006.03.009

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

Review 1.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

2.  Influence of contraceptive choice on vaginal bacterial and fungal microflora.

Authors:  G Donders; G Bellen; D Janssens; B Van Bulck; P Hinoul; J Verguts
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-09       Impact factor: 3.267

3.  Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.

Authors:  Sujit D Rathod; Patricia A Buffler
Journal:  BMC Womens Health       Date:  2014-03-10       Impact factor: 2.809

4.  Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes.

Authors:  Lottie Brown; Mathilde Chamula; Sharon Weinberg; Frakinda Jbueen; Riina Rautemaa-Richardson
Journal:  J Fungi (Basel)       Date:  2022-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.